# Alchemedicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alchemedicine

- Industry: Pharmaceuticals
- Headquarters: Tsukuba, Japan
- Website: https://alchemedicine.com
- Total disclosed funding: $20M
- Latest round: Series B (Dec 19, 2022)
- Investors on record: 7

## About

Based in Japan, Alchemedicine Inc. specializes in the research and development of innovative low molecular weight pharmaceuticals, leveraging proprietary technology to enhance drug efficacy and reduce side effects.Founded in 2019, Alchemedicine Inc. is located in Tsukuba, Japan, focusing on the research and development of pharmaceutical innovations. The company has completed 3 deals, with the most recent being a Series B funding round in December 2022, raising JPY 1.4 billion from investors including Mizuho Capital and Beyond Next Ventures. The firm has successfully raised a total of JPY 1.4 billion, achieving a current company valuation of JPY 6,918.392 million.Alchemedicine Inc. specializes in the research and development of new low molecular weight pharmaceuticals, utilizing their proprietary drug synthesis technology, HiSAP®. This technology addresses significant shortcomings in existing medications, such as weak efficacy, strong side effects, and inadequate pharmacokinetics, allowing for rapid improvement of candidate drugs. The company's research is not confined to specific disease areas, seeking to meet unmet medical needs across a wide range of conditions. Alchemedicine collaborates with notable pharmaceutical companies, including Astellas Pharma Inc. and Maruho Co., Ltd., indicating a client base composed of established players in the pharmaceutical sector, serving both domestic and international clientele.The revenue structure of Alchemedicine Inc. is primarily driven by milestone payments received from partnerships and collaborative research agreements with other pharmaceutical companies. The company engages in B2B transactions, focusing on partnerships that involve joint research or licensing agreements. Upon achieving specific development milestones in collaboration with other firms, Alchemedicine receives payments that contribute to their revenue stream. The firm executed a Series B funding round that enables further investment into their research and development initiatives. Specific pricing plans or service costs are not disclosed, but the flagship technology, HiSAP®, serves as a cornerstone for their product offerings and partnership dealings.In December 2022, Alchemedicine Inc. raised JPY 1.4 billion in Series B financing, which will be utilized to bolster their in-house drug research and development efforts. The company is committed to designing and launching new pharmaceutical products to address unmet medical needs. Additionally, Alchemedicine plans to expand its market reach, targeting both domestic and international markets. The recent funding will support these initiatives, allowing the firm to invest significantly in developing innovative therapeutics and exploring new geographic regions.

## Funding rounds

- Series B, Dec 19, 2022, $11M — JAFCO Group, Mitsubishi UFJ Capital, SMBC Venture Capital, Mizuho Capital, Joyo Capital Partners, Beyond Next Ventures
- Series A, Feb 16, 2021, $7.1M — JAFCO Group, Mitsubishi UFJ Capital, SMBC Venture Capital, Joyo Capital Partners, Beyond Next Ventures, Tsukuba Institute of Research
- Seed, Oct 28, 2019, $2.4M — Mitsubishi UFJ Capital, Beyond Next Ventures

## Investors

- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Seed, Series A, Series B
- Beyond Next Ventures (https://capitalatlas.ai/funds/beyond-next-ventures) — Seed, Series A, Series B
- JAFCO Group (https://capitalatlas.ai/funds/jafco-group) — Series A, Series B
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series A, Series B
- Joyo Capital Partners (https://capitalatlas.ai/funds/joyo-capital-partners) — Series A, Series B
- Tsukuba Institute of Research (https://capitalatlas.ai/funds/tsukuba-institute-of-research) — Series A
- Mizuho Capital (https://capitalatlas.ai/funds/mizuho-capital) — Series B